Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Brescia Morra V, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Furlan R, Salvetti M; MuSC-19 Study Group. Sormani MP, et al. Among authors: fragoso yd. Mult Scler. 2022 Jun;28(7):1034-1040. doi: 10.1177/13524585211035318. Epub 2021 Jul 30. Mult Scler. 2022. PMID: 34328824
Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
Fragoso YD, Mendes MF, Arruda WO, Becker J, Brooks JB, Carvalho Mde J, Comini-Frota ER, Domingues RB, Ferreira ML, Finkelsztejn A, Gama PD, Gomes S, Gonçalves MV, Kaimen-Maciel DR, Morales Rde R, Muniz A, Ruocco HH, Salgado PR, Albuquerque LB, Gama RA, Georgeto S, Lopes J, Oliveira CL, Oliveira FT, Safanelli J, Saldanha PC, Satomi M. Fragoso YD, et al. Arq Neuropsiquiatr. 2013 Oct;71(10):780-2. doi: 10.1590/0004-282X20130121. Arq Neuropsiquiatr. 2013. PMID: 24212514 Free article.
Multiple sclerosis starting before the age of 18 years: the Brazilian experience.
Fragoso YD, Ferreira ML, Morales Nde M, Arruda WO, Brooks JB, Carneiro DS, Carvalho Mde J, Comini-Frota ER, Correa EC, Damasceno CA, Domingues RB, Finkelsztejn A, Gama PD, Gomes S, Gonçalves MV, Grzesiuk AK, Khouri JM, Kaimen-Maciel DR, Mendes MF, Morales Rde R, Ribeiro SB, Ribeiro TA, Albuquerque LB, Anacleto A, Finkelsztejn J, Gama RA, Lopes J, Oliveira CL, Oliveira FT, Pires LA, Saldanha PC, Souza AH, Silva AE. Fragoso YD, et al. Arq Neuropsiquiatr. 2013 Oct;71(10):783-7. doi: 10.1590/0004-282X20130122. Arq Neuropsiquiatr. 2013. PMID: 24212515 Free article.
We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?
Fragoso YD, Arruda NM, Arruda WO, Brooks JB, Correa EC, Damasceno A, Damasceno CA, Ferreira ML, Giacomo MC, Gomes S, Gonçalves MV, Grzesiuk AK, Kaimen-Maciel DR, Lopes J, Machado SC, Oliveira CL, Stella CR. Fragoso YD, et al. Expert Rev Neurother. 2014 Feb;14(2):127-30. doi: 10.1586/14737175.2014.874947. Epub 2014 Jan 13. Expert Rev Neurother. 2014. PMID: 24417188 Review.
How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?
Fragoso YD, Adoni T, Anacleto A, Brooks JB, Carvalho Mde J, Claudino R, Damasceno A, Ferreira ML, Gama PD, Goncalves MV, Grzesiuk AK, Matta AP, Parolin MF. Fragoso YD, et al. Expert Rev Neurother. 2014 Nov;14(11):1251-60. doi: 10.1586/14737175.2014.962517. Epub 2014 Sep 22. Expert Rev Neurother. 2014. PMID: 25242167 Review.
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Sánchez-Menoyo JL, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators. Fragoso YD, et al. Mult Scler Relat Disord. 2018 Jan;19:105-108. doi: 10.1016/j.msard.2017.11.018. Epub 2017 Nov 22. Mult Scler Relat Disord. 2018. PMID: 29182993
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)].
Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Menoyo JLS, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators. Fragoso YD, et al. Mult Scler Relat Disord. 2018 May;22:166. doi: 10.1016/j.msard.2018.02.025. Epub 2018 Feb 24. Mult Scler Relat Disord. 2018. PMID: 29807821 No abstract available.
Risk of secondary progressive multiple sclerosis: A longitudinal study.
Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand'Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T. Fambiatos A, et al. Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9. Mult Scler. 2020. PMID: 31397221
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
Zhou Y, Claflin SB, Stankovich J, van der Mei I, Simpson S Jr, Roxburgh RH, Kalincik T, Blizzard L, Lugaresi A, Alroughani R, Sajedi SA, Butzkueven H, Pucci E, Spitaleri D, Granella F, Cristiano E, Yamout B, Hughes S, Gouider R, Sánchez Menoyo JL, Olascoaga J, McGuigan C, Shaw C, Kermode AG, Kasa K, Al-Harbi T, Altintas A, Laureys G, Fragoso Y, Hardy TA, Csepany T, Sirbu CA, Decoo D, Sas A, Alvarez-Cermeño JC, Kotkata K, Millán-Pascual J, Taylor BV. Zhou Y, et al. Mult Scler. 2020 Nov;26(13):1765-1774. doi: 10.1177/1352458519881994. Epub 2019 Oct 31. Mult Scler. 2020. PMID: 31668127
208 results